Mission
To disseminate information and provide leadership related to health economics and outcomes research of precision medicine and advanced therapies.
Goal
- Establish a forum for members to engage in discussion related to the challenges of translating precision medicine and advanced therapies into clinical practice.
- Promote education related to the health economics of precision medicine and advanced therapies.
- Investigate the demonstration of value and the use of innovative payment models for precision medicine, cell therapies, gene therapies, and tissue-engineered products
Background
The term "precision medicine" is often described as providing "the right patient with the right drug at the right dose at the right time.” More broadly, precision medicine (also known as personalized medicine) may be thought of as the tailoring of a medical treatment to the individual’s characteristics, needs, and preferences during all stages of care, including prevention, diagnosis, treatment, and follow-up. Advance therapies (also known as regenerative medicine), which include cell therapies, gene therapies, and tissue-engineered products are used in the precision medicine approach to care. These advanced therapies are often one-time treatments that are potentially curative. Together, precision medicine and advanced therapies reflect some of the most cutting-edge medical technologies available, but these therapies have unique considerations and are very different than traditional medications. The Precision Medicine and Advanced Therapies Special Interest Group seeks to explore issues related to the approval, payment, utilization, and evidence development related to the use of these technologies so they can be better used to improve the population’s health.
Leadership:
Emily Reese, PhD, MPH
Molly Purser, MBA, BS, PhD
Working Groups:
Key Project
Being precise about precision medicine: What should value frameworks incorporate to address precision medicine? - A report of the Personalized Precision Medicine Special Interest Group
Submitted to Value in Health
Real-world evidence to address uncertainty for transformative and curative therapies
Co-chairs:
- Eric Faulkner, MPH, Vice President, Real World Value and Strategy, Executive Director, Precision and Transformative Medicine Center of Excellence, Evidera
- Sue Zelt, DrPH, Principal and consultant, Cere Health Research
Member Engagement:
Journal Club
We will hold 4 meetings each year. Each journal club will commence with a brief overview of the article by the author, followed by a moderated discussion of the article.
Chair:
- Melanie D. Whittington, PhD, Research Assistant Professor, Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Events:
January 16, 2020, 11 AM EST - “Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma” with Drs. Melanie Whittington and Jonathan Campbell, faculty, the University of Colorado Anschutz Medical Campus
Others TBD
Work Products
- Challenges in the Development and Reimbursement of Personalized Medicine - Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Development and Reimbursement Working Group
- Precision Medicine and Advanced Therapies 101, Oct 23, 2019